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The role of metabolic activation/deactivation reactions during development is evaluated in relation to
developmental pharmacology and toxicology. Enzyme systems evaluated include the mixed-function
oxidases (aryl hydrocarbon hydroxylase and oxidative demethylation), epoxide hydration and conjugation
(glutathione conjugation, sulfation, and glucuronidation). Placental transfer and milk secretion ofchemi-
cals are discussed in relation to maternal, placental, and fetal metabolism. Normal patterns of enzyme
development can be modified in two ways: (1) enzyme induction and (2) enzyme imprinting. Postnatal
induction ofthe mixed-function oxidases and glucuronyl-transferase following treatment ofpregnant rats
with TCDD is shown to be caused primarily by newborn exposure to TCDD in milk. Structure-activity
relationship are defmed for the perinatal induction of hepatic enzymes by the pure PCBs. PCBs are
divided into two classes: P-450 inducers and P-448 inducers. Imprinting or programming of hepatic
metabolism is a function of the sexual differentiation of enzyme activity; male and female activities are
similar in prepubertal animals, whereas pronounced sex differences are evident in adults. Treatment of
newborn rats (days 2-6) with diethylstilbestrol or testosterone resulted in a feminization (decrease) of
mixed-function oxidation and glucuronidation in adult males. No changes were seen in immature males or
females or adult females. This effect appears to be irreversible and is under pituitary-hypothalamic-
gonadal control. In addition to the feminization of enzyme activity, neonatal exposure to hormonally
active chemicals also feminizes the hepatic response to cadmium in resultant adult animals.
The role of metabolism in xenobiotic phar-
macokinetics and toxicity has received considerable
attention over the last two decades. The concept of
metabolic activation of chemicals to reactive inter-
mediates is critical in attempts to characterize the
sequence of molecular events eventually leading to
environmental carcinogenesis, mutagenesis and
teratogenesis.
A theoretical scheme whereby chemicals might
initiate carcinogenesis could begin by exposure to
an inactive precursor. The precursor could be con-
verted to a reactive intermediate, presumably by
the hepatic or extrahepatic monooxygenase system
catalyzed by cytochrome P-448 or P-450. Reactive
intermediates are thought to be electrophilic (often
epoxides), and they can bind covalently to nucle-
ophilic nitrogen, oxygen, or sulfur atoms or cellular
macromolecules (1). Damaged macromolecules can
result from this interaction resulting in the initiation
of carcinogenesis. Conversely, an inactive precur-
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sor may be enzymatically deactivated by a wide va-
riety of enzyme systems including the
monooxygenase system. Moreover, a reactive in-
termediate may be deactivated prior to the initiation
ofcarcinogenesis (Fig. 1). These considerations are
applicable to both adult and developing systems.
Factors other than metabolic deactivation may
play a role in preventing carcinogenesis and other
forms oftoxicity. For example, DNA repair process-
es may prevent the initiation oftoxicity following co-
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FIGURE 1. Diagrammatic pathways for metabolic activation/
deactivation of foreign chemicals.
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7valent binding. If, these repair processes are pres-
ent in fetal tissues they could modify the expression
of transplacental toxicity. Immunological defenses
are also operative in perinatal tissues (2) and might
function to stop the progression of toxicity at vari-
ous developmental stages.
Factors in Activation/Deactivation
Reactions
The role of activation/deactivation reactions in
drug disposition and transplacental toxicity during
development is not well understood and is compli-
cated by a large number of variables not encoun-
tered in mature systems (3). Some of these factors
are outlined in the following paragraphs.
Differing Developmental Patterns ofSpecific
Reactions
The balance between activation and deactivation
reactions for specific substrates fluctuates dramat-
ically in an age-dependent manner. It is difficult to
predict whether a specific enzyme system will
function as an activation or deactivation system.
Table 1 lists the potential dual role of several ofthe
drug-metabolizing enzymes that have been postu-
lated in experimental animals, according to factors
such as age, nature of the substrate, and site of
metabolism. One of the greatest problems in
elucidating the role of metabolism in toxicity is
characterization of the mechanisms of toxicity in-
cluding the identity of the active metabolite. There
is much controversy on this subject. Forexample, it
is not clear whether the potent transplacental car-
cinogen, diethylstilbestrol initiates its toxic actions
through an active metabolite or the estrogen action
of the parent compound (4).
Relative Importance of Maternal and Fetal
Metabolism
An important factor in transplacental toxicity
evaluation involves the capacity of fetal tissues to
metabolize xenobiotics. Ifbioactivation occurs only
in the maternal compartment, the physical prop-
erties and stability of the reactive metabolite deter-
Table 1. Dual role of drug-metabolizing enzymes.
Enzyme reaction Activation Deactivation
Epoxidation + +
Hydroxylation + +
Glucuronidation + +
Epoxide hydration + +
Sulfation + +
mine access to the fetal compartment. Clearance of
both active and inactive metabolites from the fetus
often occurs much slower than in adults.
Role ofMetabolism in Placental Transfer of
Chemicals
There are a number of factors that modify pla-
cental transfer rates ofchemicals, includingpolarity
(5). Metabolic reactions such as hydroxylation and
conjugation can occur in maternal or placental
compartments and generally decrease lipophilicity
of xenobiotics and therefore retard placental trans-
fer. In contrast, reactions such as deconjugation in-
crease lipophilicity and therefore increase transfer
rates from the maternal to fetal compartment (6).
Relative Importance of Hepatic and
Extrahepatic Metabolism during
Development
During recent years the role ofextrahepatic drug
metabolism in organ specific toxicity and phar-
macokinetics has become apparent (7). One of the
clearest examples involves colon carcinogenesis in-
duced by dimethylhydrazine as a function of intes-
tinal metabolism and associated enterohepatic cir-
culation of this chemical (8). It therefore becomes
important to ascertain the balance between activa-
tion and deactivation reactions ofspecific chemicals
in specific tissues at specific ages to understand the
role ofdrug metabolism in developmental toxicity.
Chemical and Disease-Mediated Alterations
in Developmental Patterns of
Drug-Metabolizing Enzymes
These enzyme systems are, in many cases, ex-
tremely sensitive to inductive or repressive actions
of both endogenous and exogenous chemicals (7)
and sensitivity to these actions appears to change
with development (9, 10). Disease conditions during
pregnancy might also significantly alter ontogeny of
metabolic competence. Therefore, pre-existing dis-
ease conditions or co-exposure to environmental
agents may modify toxic responses.
Sex Differences in Developmental Patterns
Sex differences exist in hepatic metabolism of
many species and usually become evident only after
sexual maturation (11). For example, rat mixed-
function oxidase activity in liver is usually much
greater in adult males than females, although differ-
ences in these enzyme systems are not apparent in
Environmental Health Perspectives 8immature animals (12). Sex differentiation of
metabolic activation/deactivation reactions may
lead to sex as well as age-dependent differences in
toxicity.
Extrapolation of Animal Data to the Human
Condition
Extrapolation is complicated by many factors.
One difficulty arises from the qualitative as well as
quantitative differences that exist in the ontogeny of
drug metabolizing enzymes ofdifferent species. For
example, human fetuses have significant levels of
mixed-function oxidase activity, whereas the onset
of activity of this system in experimental animals
does not occur until parturition (10, 13-15). How-
ever, mixed-function oxidase activity in human
fetuses may reflect transplacental exposure to
polycyclic hydrocarbons which are capable of in-
ducing enzyme activity in fetuses of experimental
animals (10, 16). Moreover, the perinatal response
of drug-metabolizing enzymes to inducing agents
differs according to strain as well as species (15).
Microsomal Ontogeny of
Monoxygenases
Aryl Hydrocarbon Hydroxylase
Aryl hydrocarbon hydroxylase (AHH) is part ofa
cytochrome P-450-dependent enzyme system
termed collectively the mixed-function oxidase or
monooxygenase system. This microsomal enzyme
complex functions to metabolize a large number of
xenobiotics having widely different structural com-
ponents and spectrum of toxic actions. AHH is
often used as an indicator ofthe capacity ofbiologi-
cal systems to form reactive electrophilic metabo-
lites which are frequently in the form ofarene oxide
intermediates (17) produced in hydroxylation reac-
tions. However, AHH assays often are a measure of
total hydroxylated or polar metabolites and are not
necessarily indicative of metabolic activation. For
example, polycyclic hydrocarbons such as benzo-
[a]pyrene generate large numbers of microsomal
oxidative metabolites possessing widely different
capacities for binding to cellular macromolecules in
in vitro systems (18-20). Information on the rates of
formation of specific active metabolites capable of
eliciting biochemical lesions is needed to achieve a
valid toxicokinetic evaluation. However, such a
definitive evaluation is not feasible for each tox-
icant. Therefore, determinations of AHH activity
by using benzpyrene, biphenyl, or other suitable
substrate may provide approximate data on the
capacity of some biological systems to activate
some substrates (those activated by the microsomal
monooxygenase system).
Characterization of the role of metabolic
activation/deactivation in transplacental toxicity is
extemely difficult in developing and differentiating
systems. Nevertheless, information on the on-
togeny of AHH is available and a schematic rep-
resentation of AHH ontogeny in rat liver is pre-
sented in Figure 2. This scheme was derived as a
composite of several studies (10, 16, 21) and unpub-
lished observations. Enzyme activity is first detect-
able just prior to birth and increases rapidly for the
first two weeks of life, corresponding to the on-
togeny of cytochrome P-450. AHH activity then
plateaus until puberty, when a sexual differentiation
of enzyme activity is expressed: male liver enzyme
activities become approximately 6-fold higher in
males than females (21). Sexual differentiation of
the monooxygenase system is pituitary-dependent
and appears to be programmed by neonatal expo-
sure to testicular androgens during a critical period
of early development (12, 22). Biphenyl hydroxyla-
tion also exhibits a sex difference in adult rats (23),
whereas hydroxylations of aniline and zoxa-
zolamine do not exhibit sex differences (11). The
neonatal development ofAHH appears to be similar
in rabbits (24), mice (25), and guinea pigs (26).
Unlike the rat, human fetuses contain significant
levels of AHH activity in early gestation (13, 27).
Moreover, AHH activity has been detected in
extrahepatic organs of human fetuses; adrenal, va-
gina, uterus, testis, ovary, intestine, kidney, lung,
and placenta (28, 29).
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FIGURE 2. Schematic representation of aryl hydrocarbon hy-
droxylase ontogeny in rat liver. This scheme was derived as a
composite of many studies (10, 16, 21, and unpublished ob-
servations).
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N-Hydroxylation is potentially an important
metabolic pathway in the evaluation of transpla-
central toxicity as a function of subsequent forma-
tion of reactive electrophilic esters of N-hydroxy
metabolites (30). Fetal and placental tissues of hu-
mans and monkeys are capable of ring- and N-
hydroxylation of the potent carcinogen 2-
acetylaminofluorene (31). N-Oxidation first occurs
in rabbits just prior to birth, followed by a gradual
increase in activity until adult levels are attained
(32).
N-Demethylation
A schematic representation of oxidative N-
demethylation ontogeny in rat liver microsomes is
presented in Figure 3, which is a composite derived
from the works of several laboratories (/2, 22, 33,
34). Enzyme activity is first detected just prior to
birth followed by an increase up to two weeks. De-
methylation rates then plateau until puberty when,
as with AHH, a pronounced sexual differentiation
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FIGURE 3. Schematic representation of oxidative N-
demethylation ontogeny in rat liver. This scheme was derived
as a composite of several studies (12, 22, 33, 34).
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FIGURE 4. Schematic representation ofglucuronidation rates of
one group of substrates by UDP glucuronyltransferase. This
scheme was derived as acomposite ofseveral studies (10, 33,
38, 39).
10
ofactivity occurs. Oxidative demethylation is easily
detected in human fetuses at levels approximately
30% those of human adults (/3, 14, 27).
Ontogeny of Conjugation
Reactions
On simplification, and depending on chemical
substrate the drug biotransformation process may
be separated into two parts: first an oxidative reac-
tion, such as hydroxylation, results in the formation
of a free hydroxyl group; this is then rapidly conju-
gated with glucuronic acid, sulfate, or another con-
jugate (35) as indicated in Eqs. (1) and (2). This
Phase
mixed-function
oxidation
cyt. P-450 <JOOOH
acid
Phase 2
glucuronyl-
transferase
OH
series of reactions renders the molecule more polar
and generally more excretable and less toxic. How-
ever, conjugation reactions may also function in the
formation of reactive electrophilic intermediates
(30, 36, 37) (Table 1).
UDP Glucuronyltransferase (UDPGT)
A schematic composite of UDPGT ontogeny for
one group of substrates in rat liver is presented in
Figure 4 (/0, 33, 38, 39). The onset of UDPGT ac-
tivity occurs 5 days prior to birth followed by a
dramatic increase in activity such that glucuronida-
tion rates at birth exceed adult levels. Glucuronida-
tion rates for a second group of substrates do not
exhibit this developmental peak (10, 38, 39), pro-
viding one criterion used to ascertain functional
heterogeneity of UDPGT. Purification procedures
have recently separated two forms of UDPGT (40,
41). UDPGT, like the microsomal monooxygenase
system, exhibits sexual differentiation.
The elucidation of the factors that regulate onset
of glucuronidation has received considerable at-
tention. Experiments which chick embryo liver
cultures have demonstrated that UDPGT activity
increases markedly in culture and actually exceeds
that found normally in adult liver (42). The conclu-
sion is that developmental onset ofglucuronidation
appears to be regulated by UDPGT synthesis. Also,
it has been reported that the onset of UDPGT in
chick embryo liverculture is under pituitary control
Environmental Health Perspectivesthrough production of active glucucorticoids (43,
44). Moreover, it appears that the differential ages
for the onset ofUDPGT activity in different tissues
is probably related to tissue-specific activation of
UDPGT synthesis (45). The characteristic de-
velopmental peak for nonsteroid UDPGT is not
seen in rabbit liver and is also not seen in kidney
and lung (45). Extrahepatic tissues in fetuses ofex-
perimental animals do not contain significant
UDPGT although some tissues such as kidney have
high levels in adults (45). UDPGT activities are low
or nondetectable in human fetuses (46).
Sulfotransferase
Sulfotransferase is a family ofcytosolic enzymes
which catalyze the transfer of active sulfate from
3'-phosphoadenosine 5'-phosphosulfate (PAPS) to
steroids and xenobiotics (35). Sulfation is generally
considered a detoxication reaction, but the sulfate
ester of the N-hydroxy metabolite of AAF is a
reactive electrophile (30, 37). Moreover, sulfated
steroids are important to hormone action (47). Al-
though data on the ontogeny of sulfotransferase is
limited, ontogeny and partial purification studies
have demonstrated enzyme multiplicity (48). Sexual
differentiation of sulfotransferase is substrate-
dependent for a variety of glucocorticoids and
steroids (48). No information was found on the
perinatal development of sulfation ofxenobiotics in
either humans or experimental animals.
N-Acetyltransferase
N-Acetylation is one ofthe principal mechanisms
for the metabolism of foreign arylamines and
arylhydrazides in most mammalian species (35).
This process involves the transfer ofthe acetyl moi-
ety of acetyl coenzyme A (acetyl CoA) to
arylamines by N-acetyltransferase. N-Acetyl-
transferase is located in the soluble portion of
mammalian liver and has been considered to be a
detoxication enzyme. Perinatal development
studies in rats and rabbits revealed that fetal and
neonatal animals are capable ofN-acetylation (49).
Rat liver developmental studies demonstrated two
peaks ofactivity with the first peak occurring in the
late fetus followed by a second peak three days after
birth. Rabbit fetal and neonatal enzyme activity in-
creased to adult levels by the second week after
birth in liver and gut; however, lung showed a dif-
ferent developmental pattern. The enzyme has been
partially purified from livers of developing rabbits,
and it was found that fetal sulfamethazine N-
acetylation rates were considerably less than those
observed for adults, and activity reached adult
levels at about one month of age (50). Kinetic de-
terminations of rabbit liver N-acetyltransferase
provided evidence to correlate developmental vari-
ations with a "'fetal" enzyme form.
Ontogeny of
Epoxide-Metabolizing Enzymes
As discussed earlier in this paper, many aromatic
and olefinic xenobiotics are metabolized to
epoxides (arene or alkene oxides) by the micro-
somal monooxygenase system. These reactive in-
termediates can bind covalently to DNA, RNA and
proteins to initiate a toxic response; carcinogenesis,
mutagenesis, teratogenesis or organ specific tox-
icity. Epoxides can be further metabolized by
epoxide hydratase to form a diol or by a complex or
cytosolic enzymes known collectively as
glutathione S-transferase. Both epoxide metaboliz-
ing enzymes function to deactivate epoxides (51).
However, epoxide diols ofbenzpyrene are reactive
electrophiles (52), suggesting that epoxide hydra-
tase may play an indirect role in the formation of
biologically reactive metabolites. Developmental
studies in mice, guinea pigs, and rabbits have dem-
onstrated that ontogeny of epoxide hydratase and
glutathione S-transferase is organ-specific; liver,
lung, intestine and kidney were investigated (53,
54). Enzyme activity of both epoxide metabolizing
systems is present in fetal tissues, in some cases
equal to adult levels. In general the ontogeny of
epoxide hydratase is similar to and is related to the
development of AHH and other microsomal
monooxygenase components (54, 55).
Modifications of Ontogeny
The microsomal monooxygenase system and
many of the conjugative enzymes, most notably
UDPGT, can be induced or repressed by a wide
variety of chemicals including polycyclic hy-
drocarbons, halogenated aromatics, barbituites,
hormones, and many others. Considerable infor-
mation is also available on the perinatal effects of
these chemicals on metabolic activation/deac-
tivation reactions following transplacental and/or
lactational exposures. Information in the present
paper will emphasize alterations in the development
of AHH and UDPGT following perinatal treatment
of experimental animals with halogenated aromat-
ics. In a second section, the capacity for neonatal
hormones to irreversibly alter the metabolic com-
petence ofsubsequent adult rats, will be evaluated.
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Gestation day or age
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FIGURE 5. Effects of treatment of pregnant rats with 3 ,ug
TCDD/kg on ontogeny of hepatic aryl hydrocarbon hy-
droxylase. Each point derived as an average of at least four
separate litters. Assay methods presented elsewhere (21).
Perinatal Induction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) has
been detected as a contaminant of some or-
ganochlorines, most notably the herbicide 2,4,5-T.
This chemical is extremely toxic and is also a potent
inducer of specific microsomal mixed-function
oxidases and UDP glucuronyltransferase in several
tissues of adult rats (56). The effects of administra-
tion of TCDD to pregnant rats on the ontogeny of
some hepatic drug-metabolizing enzymes was in-
vestigated (1O). Results reveal that AHH was mark-
edly induced in fetal rat liver(Fig. 5). Moreover, the
onset of enzyme activity was detected in fetal livers
four days prior to birth in the treated group com-
pared to two days prior to birth in the control group
(10).
Later studies have investigated the transplacental
induction of carcinogen hydroxylating systems by
TCDD (16) AHH was induced nearly 100-fold in
fetal rats but only minimal increases were evident in
placentas. Rates of ring and N-hydroxylation of
N-2-fluorenylacetamide were also markedly in-
duced. Increased formation of benzyprene diols in
both the fetal and maternal compartments was as-
sociated with the increased AHH activity in fetal rat
livers. Therefore, it appears that the lack of re-
sponse offetal enzymes to many inducing agents is
not due to the lack of an appropriate genetic
mechanism in fetal liver but is likely a function of
pharmacokinetic factors such as maternal metab-
olism, placental transfer and/or xenobiotic-receptor
interactions. In contrast to AHH, fetal hepatic
steroid and nonsteroid UDPGT are unaffected by
TCDD treatment ofthe pregnant animal (Figs. 6 and
7). Increased activity of AHH and nonsteroid
UDPGT is evident postnatally, whereas steroid
UDPGT was unchanged in the same animals. Dif-
ferences in susceptibility to TCDD inductive ac-
tions, tissue distribution, and enzyme ontogeny
have been used as criteria for the contention that
steroid and nonsteroid UDPGT are at least two
separate enzyme systems (10, 38, 39, 57). UDPGT
activity in extrahepatic tissues is also induced in
offspring of pregnant rats administered TCDD (21).
The neonates have elevated levels of UDPGT in
liver, kidney, lung, and intestine, but like adult rats,
testicular tissue is nonresponsive. Increased levels
of enzyme activity are most pronounced in the kid-
ney.
Since nonsteroid UDPGT is induced postnatally
but not prenatally following treatment of pregnant
rats with TCDD, pups were crossed-fostered im-
mediately after birth to determine whether the post-
natal stimulation of UDPGT is related to newborn
exposure to TCDD in milk or to the postnatal acti-
vation of an inducing mechanism (10). Results re-
vealed that the major factor is newborn exposure to
TCDD in milk although UDPGT in the postnatal
liver does appear to be more responsive to TCDD
than the prenatal liver. Tissue distribution experi-
ments with 14C-radiolabel demonstrate the TCDD
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FIGURE 6. Effects of treatment of pregnant rats with 3 ,ug
TCDD/kg on the ontogeny of hepatic 1-naphthol glucuronyl-
transferase activity. Each value derived from an average ofat
least four separate litters. Assay methods presented
elsewhere (38).
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FIGURE 7. Effects of treatment of pregnant rats with 3 ,ug
TCDD/kg on the ontogeny of hepatic testosterone glu-
curonyltransferase activity. Each value derived from at least
four separate litters. Assay methods presented elsewhere
(38).
does not readily cross the placenta but is apparently
secreted in high concentrations in milk. Postnatal
induction of microsomal enzymes by newborn ex-
posure to organohalogens in milk is not a unique
property of TCDD. Neonatal mice which had re-
ceived kepone and mirex exhibit dramatic eleva-
tions in oxidative 0- and N-demethylation path-
ways (58). The PBBs are also effective transpla-
cental inducers (induction characteristics are mixed
with some phenobarbital type induction and some
3-methylcholanthrene type induction) ofthe hepatic
monooxygenase system (59) but are also secreted in
high concentrations in milk resulting in increased
enzyme activity in pups receiving PBBs only via
lactation (59, 60).
The polychlorinated biphenyls (PCBs) are pro-
duced commercially as a mixture of many congen-
ers and are generally considered to be biolog-
ically-and ecologically- persistent industrial pol-
lutants. Most of the toxicology studies have been
derived by using these mixtures. Such studies pro-
vide important and necessary toxicological data but
reveal little about structure-activity relationships of
individual congeners differing in the number and
position of chlorine substitutions. PCBs have
teratogenic potential, as evidenced by skin, liver,
and growth disorders in offspring of pregnant
women exposed to PCBs in Yusho, Japan (61).
Pharmacokinetic studies reveal that the presence
of two unsubstituted carbon atoms on the biphenyl
ring markedly enhance the metabolic rate constant
of PCBs in adult rats (62). Recent studies in our
laboratory have characterized some of the phar-
macologic properties of pure PCB congeners in de-
veloping rats (63).
Analysis of structure-activity relationships gov-
erning the perinatal pharmacology ofthe PCBs and
PBBs provided guidance for selecting representa-
tive congeners for evaluating the effects ofPCBs on
ontogeny of hepatic enzymes. Accordingly, preg-
nant rats were treated with 3,4-3'4'-tetrachloro-
biphenyl (4-CB) or 2,4,5-2',4',5'-hexachloro-
biphenyl (6-CB), and developmental patterns of
several hepatic enzymes were investigated:
ethoxyresorufin deethylase (cytochrome P-448-
dependent), aminopyrine demethylase (cytochrome
P-450-dependent), 16a-hydroxylase (cytochrome
P-450-dependent), 5a-reductase, and UDPGT. Data
revealed (manuscript in preparation) several in-
teresting findings. 4-CB induces cytochrome P-
448-dependent enzymes and 6-CB induces P-450-
dependent pathways in livers of offspring exposed
to these congeners transplacentally and during lac-
tation. Thus, the perinatal and adult livers respond
to PCBs in much the same way (64-66). Our studies
demonstrate that in developing rats, like adults,
individual congeners are P-450 or P-448 inducers
and that neonates may be more sensitive to PCB-
mediated increases in enzyme activities than
adults. However, conclusions regarding age-
dependent sensitivities to induction of hepatic en-
zymes must await quantitation of parent compound
and/or toxic metabolites of individual congeners in
various tissues during perinatal development.
UDPGT, which is not P-450 or P-448 dependent is
induced by both 4-CB and 6-CB in neonatal rat liv-
ers. In contrast to other hepatic enzymes, activities
of the hepatic steroid-metabolizing enzyme, 5a-
reductase, are markedly repressed by 6-CB but not
4-CB in neonatal rats (67). The mechanism of re-
pression and the physiological significance of this
finding have not been characterized.
Imprinting of Enzyme Activity
Enzyme induction, as discussed in an earlier part
ofthis report, probably results from direct action of
the chemical or chemical-receptor with genetic
material resulting in an immediate modulation of
enzyme levels as a function of increased enzyme
synthesis. A second form of enzyme modulation
which is initiated neonatally has been termed 'im-
printing" or programming of enzyme activity. Im-
printing is manifested through neonatal exposure to
hormones or hormonally active agents and results
in an irreversible determination of behavioral
characteristics and/or enzyme levels in the sub-
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13Table 2. Effects of neonatal diethylstilbestrol or testosterone proprionate (TP) on the sexual differentiation of rat hepatic enzymes.'
Adult male/female specific activity ratios
Enzyme Control Neonatal DES Neonatal TP Hypophysectomized
Ethylmorphine demethylase 4.2 1.3 1.6 1.0
Cytochrome P-450 1.1 1.0 1.0 1.0
UDPGT 1.9 1.2 1.4 1.0
tw Data summarized from the literature (22. 70, 71).
Table 3. Effects of neonatal DES or TP on the response of hepatic
enzymes to cadmium in adult rats."
Repression by Cd (2 mg/kg, IP)
Enzyme Control Neonatal DES Neonatal TP
Ethylmorphine
demethylase, male + - -
Ethylmorphine
demethylase, female - - -
Cytochrome P-450, male +
Cytochrome
P-450, female - - -
" Data summarized from the literature (22, 70).
sequent adult animal (68, 69). These imprinted end-
points are, however, not evident in the prepubertal
animal, suggesting a latency of gene expression re-
sulting from hormone action during early develop-
ment. The developmental patterns for many en-
zymes exhibit no sex differences in prepubertal
animals. However, a postpubertal sexual differ-
entiation of metabolic competence often occurs
with the activities ofone sex being markedly differ-
ent than the other. Sexual differentiation ofenzyme
activity appears to be a function of neonatal estro-
gen or androgen exposure. UDPGT and many
oxidative pathways exhibit higher activities in adult
males than females (Figs. 2 and 4), as well as differ-
ences in kinetic constants (12). Following adminis-
tration of DES or testosterone to neonatal rats the
postpubertal sexual differentiation of the micro-
somal monooxygenase system is abolished (22, 70).
This feminization of enzyme activity in male rats is
accompanied by a feminization ofthe KM,, value and
turnover number for ethylmorphine demethylation
suggesting that neonatal exposure to hormonally-
active chemicals programs for both qualitative and
quantitative alterations of the ontogeny of the mi-
crosomal monoxygenase system. Similar feminiza-
tion effects were observed for UDPGT develop-
ment following administration of DES or testo-
sterone to neonatal male rats; ontogeny of female
UDPGT is unaffected (71). Hypophysectomy of
adult rats also abolishes the sex differences in the
microsomal monooxygenase and UDPGT systems
(Table 2) providing evidence for the contention that
neonatal hormone exposure programs the
pituitary-hypothalamix axis, during a critical period
of early development, for the sexual differentiation
of many hepatic enzymes (12, 68-71). Studies on
reproductive tract development and hormone levels
in animals exposed neonatally to hormonally active
chemicals suggests that altered gonadal develop-
ment can also modify hepatic enzyme ontogeny
(71).
The neonatal feminization of hepatic develop-
ment also results in a feminized response of the
adult liver to cadmium (22, 70). Cadmium adminis-
tered to adult male rats represses the mono-
oxygenase system whereas female enzymes are un-
affected by cadmium (70). However, following
neonatal TP or DES, resultant adult male and
female rats respond in a similar manner (Table 3)
(22, 70). These changes in toxic response are appar-
ently irreversible and are manifested long after the
affector (DES) is metabolized and excreted. Further
studies are attempting to characterize the toxico-
logical significance of alterations in the normal pro-
graming of enzyme activity emphasizing the po-
tential role in developmental toxicity testing of en-
vironmental agents.
Thanks are extended to Ms. Sharon Smallwood for editorial
assistance in the preparation of this manuscript.
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